PART 4: Growth Hormone Peptides and the “Optimization” Market

CJC-1295, Ipamorelin, Sermorelin, AOD-9604 and Tesamorelin: Can We Really Hack Growth Hormone Safely?

Increasing a hormone is easy to measure. Proving that doing so makes a healthy person live longer, function better or age more slowly is a very different question.

By Alex Foxman, MD, FACP, ABOM

Double Board-Certified in Internal Medicine and Obesity Medicine

“Doc, what about peptides for muscle, fat loss and anti-aging?”

This is where the peptide conversation gets particularly interesting.

CJC-1295. Ipamorelin. Sermorelin. AOD-9604. Tesamorelin. And often ibutamoren, which is commonly grouped with peptides even though it is not actually a peptide.

They are promoted for increasing growth hormone, building muscle, burning visceral fat, improving sleep, accelerating recovery and even “reversing aging.”

The biology behind some of these compounds is real.

BUT once again:

Real biology does not automatically equal proven medicine.

First: What Are We Trying to Manipulate?

Growth hormone, or GH, is produced by the pituitary gland. Its release is controlled partly by growth hormone-releasing hormone from the hypothalamus and other signaling systems. GH then influences tissues directly and stimulates production of IGF-1, another powerful growth signal.

This system affects growth, metabolism, body composition and tissue function.

That sounds like an attractive target for “optimization.”

But here is the problem:

More is not automatically better.

If a drug increases GH or IGF-1, that proves the drug affected the pathway.

It does not prove that a healthy adult will build meaningful muscle, lose dangerous fat, avoid disease, improve healthspan or live longer.

And it certainly does not establish long-term safety.

CJC-1295: Raising GH Is Not the Same as Improving Health

CJC-1295 is a synthetic analog of growth hormone-releasing hormone. Certain versions were engineered to remain active considerably longer than natural GHRH.

Small studies in healthy adults showed that CJC-1295 could increase GH and IGF-1 levels.

That is frequently where the online story ends.

But FDA reviewers found no human effectiveness data for CJC-1295 in patients with growth hormone deficiency, the condition for which the substance was being evaluated for possible compounding. The available human studies were small, short and conducted in healthy adults. Reported effects included dose-dependent increases in heart rate, injection-site reactions, dizziness, hypotension and other symptoms requiring further study.

Then came an unusually important FDA advisory vote.

In December 2024, the FDA Pharmacy Compounding Advisory Committee overwhelmingly recommended against placing the various CJC-1295 forms it reviewed on the 503A Bulks List. For most forms the vote was 13–0 against inclusion; CJC-1295 acetate was 12–1 against.

FDA’s current compounding safety page continues to identify CJC-1295 as having limited clinical data and potential concerns involving immunogenicity, impurities and serious adverse reactions; the prior nomination is now listed as withdrawn.

CJC-1295 can raise GH.

What has not been established is that routinely raising GH with CJC-1295 makes otherwise healthy adults healthier.

Those are very different claims.

Ipamorelin: Popularity Is Not Evidence

Ipamorelin stimulates the ghrelin receptor and causes growth hormone release through a somewhat different mechanism from CJC-1295.

It is often promoted in “optimization” clinics for muscle, sleep, fat loss and recovery—and frequently combined with CJC-1295.

But FDA’s extensive review found insufficient evidence supporting ipamorelin for growth hormone deficiency or postoperative ileus through the proposed subcutaneous route. FDA also raised concerns about peptide impurities, aggregation and possible immune reactions.

An intravenous study in postoperative patients reported hypokalemia, hyperglycemia, nausea, vomiting and other adverse events; two deaths occurred among ipamorelin-treated participants, although FDA specifically noted that it was unclear whether ipamorelin caused those deaths.

In October 2024, the FDA advisory committee voted 0–12, with one abstention, against recommending either ipamorelin free base or ipamorelin acetate for the 503A Bulks List.

One committee member made a point worth remembering:

High prescribing frequency does not prove that a drug is safe and effective. 

As of 2026, FDA still lists ipamorelin acetate among bulk substances that may present significant safety risks for certain compounded uses.

Sermorelin: A More Complicated Story

Sermorelin deserves more nuance.

It is a 29-amino-acid analog of naturally occurring growth hormone-releasing hormone.

Unlike many peptides discussed in this series, sermorelin has legitimate FDA regulatory history: Geref (sermorelin acetate) received FDA approval in 1997 for growth hormone deficiency in children with growth failure. 

But that historical approval does not mean every sermorelin product being sold today is FDA-approved—and it certainly does not establish sermorelin as an anti-aging or longevity treatment.

FDA has taken enforcement action against online sellers marketing sermorelin products for human use when no approved application existed for those products.

This is exactly why the phrase “FDA-approved peptide” requires context.

Approved which product?

At what dose?

For what population?

For what condition?

Using evidence from pediatric growth hormone deficiency to market sermorelin as a fountain-of-youth injection for healthy 55-year-olds is an enormous scientific leap.

AOD-9604: The Fat-Burning Peptide With an Awkward Clinical Trial

AOD-9604 is a modified fragment of human growth hormone developed with the hope of affecting fat metabolism without producing all of growth hormone's other effects.

Online, it is marketed aggressively as a “fat-burning peptide.”

But here we have something particularly useful:

A reasonably large human trial was actually performed.

A randomized study enrolled 536 adults with obesity and compared oral AOD-9604 with placebo alongside diet and exercise.

It failed its primary weight-loss endpoint.

FDA’s review noted that there was no statistically significant difference in weight loss at 12 weeks, and the company developing AOD-9604 subsequently terminated its obesity development program. FDA also found no human data supporting the subcutaneous route now commonly marketed by wellness clinics.

In December 2024, the FDA advisory committee voted 12–0 against recommending AOD-9604-related substances for the 503A Bulks List.

This is one of my favorite examples in the entire peptide series.

Because when someone tells you:

“The mechanism makes perfect sense.”

Remember:

The clinical trial still gets the final vote.

Ibutamoren: Not a Peptide—but Part of the Same Hype

Ibutamoren, also called MK-677, is often sold alongside peptides.

Technically, it is not a peptide. It is an orally active growth hormone secretagogue that stimulates the ghrelin receptor.

It has been investigated for conditions ranging from growth hormone deficiency to sarcopenia and osteoporosis.

But in October 2024, the FDA advisory committee voted 13–1 against including ibutamoren on the 503A Bulks List. Committee members cited insufficient evidence of clinical efficacy and safety and raised concerns including fluid retention, hyperglycemia and congestive heart failure.

Again, activating a pathway is not the same as improving long-term health.

Then There Is Tesamorelin—and This Is Why Evidence Matters

Tesamorelin provides an important contrast.

It is also a growth hormone-releasing hormone analog.

But unlike CJC-1295 or ipamorelin, tesamorelin went through substantial clinical development and became an FDA-approved medication.

Current EGRIFTA WR is indicated specifically for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. It is explicitly not approved for general weight-loss management. 

Two large Phase 3 studies involving more than 800 participants demonstrated approximately a 15% treatment effect on visceral abdominal fat at 26 weeks, with benefits maintained during continued treatment.

That is what meaningful human evidence looks like.

But notice something else.

Even an FDA-approved growth hormone-releasing peptide carries important precautions.

Current prescribing information calls for monitoring IGF-1 and glucose and warns about fluid retention, glucose intolerance or diabetes and concerns involving malignancy.

Active cancer is a contraindication.

That should tell us something.

Manipulating the GH/IGF-1 pathway is not biologically trivial.

If the FDA-approved member of this family requires careful patient selection and monitoring, why would we assume that less-studied versions sold for “optimization” are automatically harmless?

And Then Comes “Stacking”

This may concern me even more.

Patients are sometimes prescribed combinations such as CJC-1295 plus ipamorelin—or multiple peptides layered on top of testosterone, growth hormone, GLP-1 drugs and supplements.

The problem is simple:

Evidence about Drug A plus evidence about Drug B does not equal evidence about A + B + C + D.

Interactions can change physiology.

Side effects can overlap.

GH and IGF-1 may rise further.

And when something goes wrong, identifying the responsible drug becomes much harder.

A “stack” may sound sophisticated.

Without appropriate clinical research, it can also be a sophisticated experiment.

My Double Board Certified Physician Verdict

Compound	Where I Put It Today
CJC-1295	Biologically active, but insufficient evidence for routine anti-aging, muscle or longevity use
Ipamorelin	Insufficient evidence and unresolved safety concerns
Sermorelin	Legitimate pharmacologic history, but current anti-aging/optimization claims go far beyond its established evidence
AOD-9604	Particularly unconvincing for weight loss because a substantial human trial failed its primary endpoint
Ibutamoren	Not a peptide; investigational, with meaningful metabolic and fluid-retention concerns
Tesamorelin	Established evidence-based peptide medicine for a very specific FDA-approved indication, not general weight loss or anti-aging

The Bottom Line

The growth hormone system is powerful.

That is precisely why I do not believe we should manipulate it casually.

Can a compound increase GH?

Maybe.

Can it increase IGF-1?

Possibly.

But those are laboratory results.

The questions that matter to me as a physician are harder:

Will you actually be healthier?

Will you function better?

Will you avoid disease?

Will you live longer?

And what might happen after five or ten years of manipulating a growth pathway?

For most of the “optimization peptides” being promoted today, we simply do not have those answers.

And once again:

“We don't know” is not anti-innovation.

It is the scientifically correct answer until the evidence arrives.

Do not confuse a higher hormone level with better health.

Do not confuse a plausible mechanism with a proven outcome.

And do not let the word “optimization” lower the scientific standard you would demand from any other medication.

Next: Part 5—The Longevity and Brain Peptides

MOTS-c. Semax. Selank. Epitalon. KPV. DSIP. Thymosin alpha-1.

These are being promoted for longevity, cognition, mitochondrial health, sleep, inflammation and even slowing aging itself.

And several of them were just placed directly under the microscope at the FDA's July 2026 peptide advisory meetings.

For the final installment, we will ask the biggest question of the series:

Can any peptide actually help us live longer—or has the marketing finally outrun the science completely?

Evidence over hype. Science over social media. Patient safety first.

— Alex Foxman, MD, FACP, ABOM

Double Board-Certified in Internal Medicine & Obesity Medicine

Beverly Hills Institute

Regulatory information reviewed through August 10, 2026. This article is intended for general educational purposes and does not constitute individualized medical advice.